Recent submissions
Now showing items 3761-3780 of 4727
-
Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.
(2016-08)A case-control study from two randomised breast cancer prevention trials of tamoxifen and raloxifene (P-1 and P-2) identified single-nucleotide polymorphisms (SNPs) in or near genes ZNF423 and CTSO as factors which predict ... -
Mind Bomb Regulates Cell Death during TNF Signaling by Suppressing RIPK1's Cytotoxic Potential.
(CELL PRESS, 2018-04-10)Tumor necrosis factor (TNF) is an inflammatory cytokine that can signal cell survival or cell death. The mechanisms that switch between these distinct outcomes remain poorly defined. Here, we show that the E3 ubiquitin ... -
Impact of atopy on risk of glioma: a Mendelian randomisation study.
(BMC, 2018-03-15)BACKGROUND: An inverse relationship between allergies with glioma risk has been reported in several but not all epidemiological observational studies. We performed an analysis of genetic variants associated with atopy to ... -
TransHERA: The cell cycle regulator p27 predicts benefit from trastuzumab treatment in HER2-positive early breast cancer patients treated within the HERA trial
(AMER ASSOC CANCER RESEARCH, 2015-05-01) -
Glycogen synthase kinase 3 controls migration of the neural crest lineage in mouse and Xenopus.
(NATURE PUBLISHING GROUP, 2018-03-19)Neural crest migration is critical to its physiological function. Mechanisms controlling mammalian neural crest migration are comparatively unknown, due to difficulties accessing this cell population in vivo. Here we report ... -
Influence of obesity-related risk factors in the aetiology of glioma.
(SPRINGERNATURE, 2018-04-01)BACKGROUND: Obesity and related factors have been implicated as possible aetiological factors for the development of glioma in epidemiological observation studies. We used genetic markers in a Mendelian randomisation ... -
Further characterization of changes in axial strain elastograms due to the presence of slippery tumor boundaries.
(SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS, 2018-04-01)Elastography measures tissue strain, which can be interpreted under certain simplifying assumptions to be representative of the underlying stiffness distribution. This is useful in cancer diagnosis where tumors tend to ... -
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
(2018-04)Importance:Multiple molecular signatures are available for managing estrogen receptor (ER)-positive breast cancer but with little direct comparative information to guide the patient's choice. Objective:To conduct a ... -
SWATH mass spectrometry as a tool for quantitative profiling of the matrisome.
(ELSEVIER, 2018-03-01)Proteomic analysis of extracellular matrix (ECM) and ECM-associated proteins, collectively known as the matrisome, is a challenging task due to the inherent complexity and insolubility of these proteins. Here we present ... -
Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer.
(NATURE PUBLISHING GROUP, 2018-03-13)Triple negative breast cancers (TNBCs) lack recurrent targetable driver mutations but demonstrate frequent copy number aberrations (CNAs). Here, we describe an integrative genomic and RNAi-based approach that identifies ... -
Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.
(BMJ PUBLISHING GROUP, 2018-01-10)OBJECTIVES: To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age. DESIGN: Analysis of genotype, PCa status, and age to ... -
Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.
(ELSEVIER SCIENCE BV, 2018-06-01)BACKGROUND: The importance of 2-yr postradiotherapy prostate biopsy status remains uncertain. OBJECTIVE: To assess the value of 2 year post treatment biopsies in a randomised trial of radiotherapy dose escalation. DESIGN, ... -
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.
(WILEY-HINDAWI, 2018-05-01)The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in single populations, with the majority of reports focused on White in Europe and North America. The Consortium of Investigators of ... -
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.
(ELSEVIER SCIENCE BV, 2018-05-01)BACKGROUND: Germline DNA damage repair gene mutation (gDDRm) is found in >10% of metastatic prostate cancer (mPC). Their prognostic and predictive impact relating to standard therapies is unclear. OBJECTIVE: To determine ... -
Value of diffusion-weighted imaging for monitoring tissue change during magnetic resonance-guided high-intensity focused ultrasound therapy in bone applications: an ex-vivo study.
(SPRINGERNATURE, 2018-05-10)BACKGROUND: Magnetic resonance (MR)-guided high-intensity focused ultrasound (HIFU) can palliate metastatic bone pain by periosteal neurolysis. We investigated the value of diffusion-weighted imaging (DWI) for monitoring ... -
Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy.
(BRITISH INST RADIOLOGY, 2018-01-01)OBJECTIVE: The aim of this study was to calculate the range of absorbed doses that could potentially be delivered by a variety of radiopharmaceuticals and typical fixed administered activities used for bone pain palliation ... -
Telomere structure and maintenance gene variants and risk of five cancer types.
(WILEY, 2016-12-15)Telomeres cap chromosome ends, protecting them from degradation, double-strand breaks, and end-to-end fusions. Telomeres are maintained by telomerase, a reverse transcriptase encoded by TERT, and an RNA template encoded ... -
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.
(AMER ASSOC ADVANCEMENT SCIENCE, 2016-06-01)Regulatory authorities have indicated that new drugs to treat type 2 diabetes (T2D) should not be associated with an unacceptable increase in cardiovascular risk. Human genetics may be able to guide development of antidiabetic ...